{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:59:25Z","timestamp":1792400365047,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.healun.2024.08.018","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:45:41Z","timestamp":1725331541000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6237-1470","authenticated-orcid":false,"given":"Stephan","family":"Rosenkranz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein-Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-2293","authenticated-orcid":false,"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-0094","authenticated-orcid":false,"given":"David","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hegab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-4380","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2024.08.018_bib1","first-page":"2200879","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"30","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.08.018_bib2","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl K","key":"10.1016\/j.healun.2024.08.018_bib3","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1093\/eurheartj\/suz206","article-title":"Management of pulmonary arterial hypertension in patients aged over 65 years","volume":"21","author":"Sitbon","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.healun.2024.08.018_bib4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.chest.2015.11.008","article-title":"Effect of age on phenotype and outcomes in pulmonary arterial hypertension trials","volume":"149","author":"Rose","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.healun.2024.08.018_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.healun.2024.08.018_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2024.08.018_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14017431.2016.1185532","article-title":"Characteristics and survival of adult Swedish PAH and CTEPH patients 2000-2014","volume":"50","author":"Radegran","year":"2016","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.healun.2024.08.018_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1183\/09059180.00007814","article-title":"The changing landscape of pulmonary arterial hypertension and implications for patient care","volume":"23","author":"Hoeper","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.healun.2024.08.018_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum","volume":"68","author":"Opitz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2024.08.018_bib10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"39","author":"Hoeper","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2024.08.018_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.healun.2022.10.003","article-title":"Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: a COMPERA analysis","volume":"42","author":"Rosenkranz","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2024.08.018_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2024.08.018_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2024.08.018_bib14","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.08.018_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.healun.2024.08.018_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.healun.2024.08.018_bib17","doi-asserted-by":"crossref","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.08.018_bib18","doi-asserted-by":"crossref","first-page":"2102419","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry","volume":"59","author":"Boucly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.08.018_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.2369","article-title":"The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study","volume":"24","author":"Rosenkranz","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2024.08.018_bib20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.08.018_bib21","doi-asserted-by":"crossref","first-page":"1602425","DOI":"10.1183\/13993003.02425-2016","article-title":"RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2024.08.018_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106241","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.healun.2024.08.018_bib23","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2019.09.010","article-title":"Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial","volume":"38","author":"McLaughlin","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2024.08.018_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3319","article-title":"Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities","author":"McLaughlin","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2024.08.018_bib25","doi-asserted-by":"crossref","first-page":"2102024","DOI":"10.1183\/13993003.02024-2021","article-title":"Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry","volume":"59","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"}],"updated-by":[{"DOI":"10.1016\/j.healun.2025.02.1679","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249824018072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249824018072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:14:47Z","timestamp":1762355687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249824018072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1053249824018072"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2024.08.018","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2024.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}